Hepatitis C Drug Increases Cure
The New York Times reports that a Phase 3 clinical trial for a new drug called telaprevir to treat hepatitis C cures 75 percent of those on a twelve week regimen followed by the standard treatment. Seventy percent of those cured saw results in six months. Hepatitis C virus causes inflammation of the liver and approximately 170 million people around the world are infected. The standard treatment is alpha interferon and ribavirin. Telaprevir works by inhibiting an enzyme the virus makes. The two main side effects are rash and anemia. National Viral Hepatitis Roundtable Lorren Sandt said “the community hopes that if telaprevir is approved by the F.D.A. that it will be accessible and affordable to everyone.” Telaprevir is manufactured by Vertex Pharmaceuticals.